Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 Pandemic
Randomized Controlled Trial
[키워드] 1.26
acute respiratory syndrome
adverse events
Against
age
Antibody Response
Antibody titer
assigned
BCG
BCG vaccination
cellular
clinical
confidence interval
control group
coronavirus
coronavirus disease
COVID-19
COVID-19 infection
cumulative
cytokine response
death
diagnosed with COVID-19
end point
EU Clinical Trial
Follow-up
Frequency
groups
had no
hazard ratio
Heterologous
humoral immune responses
Immunity
incidence
incidence of COVID-19
individuals
Infection
Influenza
intracutaneous
medical intervention
multicenter
Older
Patient
Placebo
placebo-controlled trial
polymerase chain
positive
primary end point
Randomly
required
respiratory
respiratory infections
respiratory tract infection
SARS-CoV-2
SARS-COV-2 infection
secondary
severity
significantly
stimulated
subdistribution
tested
tract
trained immunity
Trial
Tuberculosis
vaccination
Vaccine
Volunteer
volunteers
[DOI] 10.1093/cid/ciac182 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1093/cid/ciac182 PMC 바로가기 [Article Type] Randomized Controlled Trial